343 related articles for article (PubMed ID: 37069419)
1. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
[TBL] [Abstract][Full Text] [Related]
2. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.
Sung KC; Yoo TK; Lee MY; Byrne CD; Zheng MH; Targher G
Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):482-491. PubMed ID: 36727522
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
4. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
5. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
[TBL] [Abstract][Full Text] [Related]
6. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
[TBL] [Abstract][Full Text] [Related]
7. Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease.
Perdomo CM; Núñez-Córdoba JM; Ezponda A; Mendoza FJ; Ampuero J; Bastarrika G; Frühbeck G; Escalada J
Front Med (Lausanne); 2022; 9():1023583. PubMed ID: 36341262
[TBL] [Abstract][Full Text] [Related]
8. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
9. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis.
Bessho R; Kashiwagi K; Ikura A; Yamataka K; Inaishi J; Takaishi H; Kanai T
PLoS One; 2022; 17(5):e0269265. PubMed ID: 35639744
[TBL] [Abstract][Full Text] [Related]
10. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.
Kang MK; Song J; Loomba R; Park S; Tak W; Kweon Y; Lee Y; Park JG
Res Sq; 2024 Mar; ():. PubMed ID: 38496485
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Lee H; Lee YH; Kim SU; Kim HC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
[TBL] [Abstract][Full Text] [Related]
13. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
[TBL] [Abstract][Full Text] [Related]
14. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
Tang SY; Tan JS; Pang XZ; Lee GH
World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
[TBL] [Abstract][Full Text] [Related]
16. Metabolic-Associated Fatty Liver Disease (MAFLD) is associated with immune activation, increased epicardial fat volume, and steatohepatitis among people with HIV in a Thai cohort.
Han WM; Apornpong T; Chattranukulchai P; Siwamogsatham S; Lwin HMS; Boonrungsirisap J; Wichiansan T; Gatechompol S; Ubolyam S; Kerr SJ; Tangkijvanich P; Avihingsanon A
HIV Med; 2023 Sep; 24(9):1000-1012. PubMed ID: 37165782
[TBL] [Abstract][Full Text] [Related]
17. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
18. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
[TBL] [Abstract][Full Text] [Related]
19. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
[TBL] [Abstract][Full Text] [Related]
20. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]